Validated Platform

Validated Platform

Targeting complex interactions in diverse clinical ecosystems

Our discovery engine has led to impactful therapies that change disease progression across several clinical modalities:

In commercial development

Pulmonary disease

Synedgen’s pulmonary platform, is now out-licensed to Synspira Inc. (Framingham, MA), and the lead asset is currently in Phase 2 clinical trials.

Oral health

Synedgen’s range of oral health products for oral wellness, caries prevention, xerostomia, and oral ulcerations are available for purchase through Prisyna and Amazon.

Wound care

Synedgen’s wound care products, SynePure™ Wound Rinse and Catasyn™ Advanced Technology Wound Hydrogel, are currently in commercialization stages and will soon be available for purchase in the U.S. through our partners.

GI mucositis

Synedgen’s therapies provide relief from gastrointestinal side effects of cancer radiation therapy and are in early stages of product development.

In research and development

Sinus health

Synedgen has recently completed pilot clinical trials for its sinus health product.  This portfolio is being developed for acute and chronic rhinosinusitis.

Ophthalmic health

Synedgen has been awarded a 3 year grant from the National Eye Institute (NEI) of the National Institutes of Health (NIH) to develop molecules intended to counteract severe, ulcerative eye injury.